Instrument Inactif

Communiqués DermTech, Inc. Nasdaq

Actions

VGG2379F1247

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

DermTech Reports First-Quarter 2024 Financial Results	14/05	BU
DermTech : Accelaration/Increase of Financial Obligation - Form 8-K	10/05	PU
DermTech to Explore Strategic Alternatives and Implement Restructuring Plan	18/04	BU
DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/04	BU
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	11/03	AQ
DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology	08/03	BU
DermTech : 2023 Q4 Transcript	01/03	PU
DermTech Reports Fourth-Quarter 2023 Financial Results	29/02	BU
DermTech Announces Release Date for Fourth-quarter 2023 Financial Results	13/02	BU
DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations	31/01	BU
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test across All Skin Types	19/01	AQ
DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types	18/01	BU
DERMTECH SIMPLIFIES THE DERMTECH MELANOMA TEST BY DISCONTINUING THE OPTIONAL TERT ADD-ON ASSAY	17/01	AQ
DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay	16/01	BU
DERMTECH ANNOUNCES POSITIVE TOPLINE RESULTS FROM TRUST 2 STUDY EVALUATING THE DERMTECH MELANOMA TEST	09/01	AQ
DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)	08/01	BU
DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	29/12	BU
DMTK DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action – DMTK	15/12	BU
DERMTECH ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	15/12	AQ
DMTK DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages DermTech, Inc. Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action - DMTK	15/12	PR

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués DermTech, Inc. Nasdaq

Actions

VGG2379F1247

Communiqués

Filtres